Silexion Therapeutics (SLXN)

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

De Silexion Therapeutics Corp Ordinary Shares (SLXN) aandelenkoers vandaag is , wat een NaN% beweging weergeeft sinds de markt geopend. De marktkapitalisatie van het bedrijf staat op $ 5,16 mln., met een dagelijks tradevolume van aandelen. De vorige slotkoers was .

Klaar om aan de slag te gaan? Volg de onderstaande stappen, of lees onze gids over hoe je Silexion Therapeutics aandelen op Kraken kunt kopen vanaf € 10.